WASHINGTON — In one of his last moves before retirement, Sen. Orrin Hatch (R-Utah) slammed one of the Trump administration’s splashiest drug pricing plans and called for his colleagues to limit the power of the Trump administration to pursue the proposal.

Until now, Hatch has largely refrained from openly criticizing the Trump administration’s drug pricing plans, even as some have broken with Republican orthodoxy. Wednesday’s letter is perhaps the clearest sign to date of tensions emerging in the Republican party over the administration’s’ drug pricing policies.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

  • The HHS Newsletter explained that charging the same prices as other countries do, would lead to socialism. It shows how desperate these industry insiders are to keep exploiting and gouging the American people. It is time for Universal Healthcare. 70 percent of Americans agree. American healthcare is more of a criminal conspiracy than a healthcare system.

    Orin Hatch has taken millions of dollars from pharma, no one can expect him to act in the interests of the American people. Those pharn a industry lobbyists get what they pay for.

  • I cannot afford any subscriptions. I can send you a first edition book from Clement, Asimov, Heinlein, Clarke. I am 66, disabled, bio,chem, medical devices, with too many medical conditions to list.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy